Smith & NephewSNN +0.88%84 Days Payable is 186.89 as of Dec. 2025, which is 19% below its 10-year median of 231.39. GuruFocus rates SNN with a GF Score™ of 84/100 and a GF Value™ of $31.32 (Fairly Valued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Smith & Nephew ranks better than 85.28% on this metric.
The historical rank and industry rank for Smith & Nephew's Days Payable or its related term are showing as below:
SNN'
s Days Payable Range Over the Past 10 Years
Min: 210.27 Med: 231.39 Max: 254.37
Current: 210.27
During the past 13 years, Smith & Nephew's highest Days Payable was 254.37. The lowest was 210.27. And the median was 231.39.
SNN's Days Payable is ranked better than 85.28% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs SNN: 210.27
Smith & Nephew's Days Payable
declined
from Dec. 2024 (210.95) to Dec. 2025 (186.89).
It may suggest that Smith & Nephewaccelerated paying its suppliers.
Smith & Nephew Days Payable Related Terms
Smith & Nephew Days Payable Historical Data
* Premium members only.
The historical data trend for Smith & Nephew's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Smith & Nephew's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's Days Payable distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Smith & Nephew's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smith & Nephew (SNN) has a Days Payable of 186.89 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Smith & Nephew and its competitors. This is 19% below median its historical median of 231.39. Over the past decade, Smith & Nephew's Days Payable has ranged from 210.27 to 254.37. According to the industry distribution chart, Smith & Nephew ranks #117 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 14.7%.
Is Smith & Nephew's Days Payable too high?
Smith & Nephew's current Days Payable of 186.89 is 19% below median its 10-year median of 231.39. Over the past 10 years, this metric has ranged from a low of 210.27 to a high of 254.37. The Medical Devices & Instruments industry median Days Payable is 68.07. Smith & Nephew's value of 186.89 is 174.6% above this industry median. Based on the distribution chart, Smith & Nephew ranks #117 out of 795 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Smith & Nephew has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #117 out of 795 companies for Days Payable. This places Smith & Nephew in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.07. Smith & Nephew's value of 186.89 is 174.6% above this benchmark. Historically, Smith & Nephew's own Days Payable has ranged from 210.27 to 254.37 over the past decade. While the company's 10-year median is 231.39 vs. the industry median of 68.07, Smith & Nephew has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smith & Nephew's current Days Payable of 186.89 is 174.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Smith & Nephew and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current Days Payable is 186.89, which is 19% below median its own 10-year median of 231.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (SNN) is currently considered Fairly Valued. The stock's GF Value™ is $31.32, compared to a current price of $30.31 — trading 3.2% below its estimated fair value. The current Days Payable is 186.89, which is 19% below median its 10-year median of 231.39 and 174.6% above the Medical Devices & Instruments industry median of 68.07. Smith & Nephew's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Smith & Nephew (SNN), the current Days Payable is 186.89 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (SNN) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of $30.31 is trading 3.2% below its estimated GF Value™ of $31.32.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for SNN:
Days Payable: 186.89 (19% below median its 10-year median of 231.39)
GF Value™: $31.32 vs. price of $30.31 (3.2% below fair value)
Industry Position: 174.6% above the Medical Devices & Instruments median (#117 of 795)
No single metric tells the full story. See the SNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
84GF Score
Get the complete analysis for SNN
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNN has been successfully added to your 
